Mars Petcare acquires OptiGenApril 12, 2018 Mars Petcare acquired OptiGen LLC, a DNA diagnostics company specializing in canine inherited eye disorders. Included in the acquisition are exclusive licenses to a portfolio of genetic disease tests patented in the U.S., Australia, and many countries in Europe, and an extensive biobank of more than 150,000 samples collected over 20 years representing various canine eye diseases. Moving forward these samples will be used to discover new genetic health markers for dogs. With this acquisition, Wisdom Panel genetic test kits will now be able to detect more than 185 genetic disease mutations that will help breeders select the best breeding matches for genetically healthy offspring. "Through our Wisdom Health business, Mars Petcare is leading the discovery of new genetic markers for pet health," said Leonid Sudakov, president of Connected Solutions, the global ventures, consumer technology, and genetics division of Mars Petcare. "As our scientists seek to improve the understanding of the genetic basis of pet health and disease, this acquisition will contribute to the development of personalized veterinary care. We see our continued efforts to contribute to the ground-breaking companion animal genetics science as a great way to deliver on our purpose: …
SPONSORED CONTENTStart Treating Canine MMVD Patients at Stage B2Learn about early treatment with pimobendan for canine Stage B2 preclinical MMVD patients. + Learn More
